肿瘤|JITC:T细胞比值很关键!免疫治疗无进展生存期大不同( 三 )


[4] Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial [published correction appears in Lancet Oncol. 2017 Jul;18(7):e371]. Lancet Oncol. 2017;18(7):895-903. doi:10.1016/S1470-2045(17)30380-7
【肿瘤|JITC:T细胞比值很关键!免疫治疗无进展生存期大不同】[6] Mazzaschi G, Minari R, Zecca A, et al. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. Lung Cancer. 2020;148:1-11. doi:10.1016/j.lungcan.2020.07.028